Novartis Ag

Romain Wolf

Nicolas Soldermann

Alexander Baxter Smith

Pascal Furet

Frederic Zecri

Nigel Graham Cooke

Frank Stowasser

Anette Von Matt

Ian Lewis

Christina Hebach

Gregory John Hollingworth

Paulo Antonio Fernandes Gomes Dos Santos

Giorgio Caravatti

Konstanze Hurth

Sylvie Chamoin

Henrik Moebitz

Nicola Tufilli

Karen Kammertoens

Ross Strang

Klemens Hogenauer

Klemens Hoegenauer

Nadege Graveleau

Frédéric Stauffer

Frédéric Zecri

Klemens Högenauer

Nicola Tuffilli

Frédèric Zecri

Christoph Kalis

Ross Sinclair Strang

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

Use of inhibitors of the activity or function of PI3K

The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R, R, Rand Rare as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R, Rand m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Tetrahydro-pyrido-pyrimidine derivatives

Growing community of inventors

Schlierbach, France

Romain Wolf